

### miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer

Evita Maria Lindholm<sup>1</sup> (p), Miriam Ragle Aure<sup>1</sup>, Mads Haugland Haugen<sup>1,2</sup>, Kristine Kleivi Sahlberg<sup>1,3</sup>, Vessela N. Kristensen<sup>1,4</sup>, Daniel Nebdal<sup>1</sup>, Anne-Lise Børresen-Dale<sup>1,5</sup>, Ole Christian Lingjærde<sup>1,6</sup> and Olav Engebraaten<sup>2,5,7</sup>

- 1 Department of Cancer Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway
- 2 Department of Tumor biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Norway
- 3 Department of Research and Innovation, Vestre Viken Hospital Trust, Drammen, Norway
- 4 Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway
- 5 Insitute for Clinical Medicine, University of Oslo, Norway
- 6 Department of Computer Science, Faculty of Mathematics and Natural Sciences, University of Oslo, Norway
- 7 Department of Oncology, Oslo University Hospital, Norway

#### Keywords

angiogenesis; bevacizumab; breast cancer; miRNA; neoadjuvant

#### Correspondence

O. Engebraaten, Department of Oncology, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway Tel: +4723026600 E-mail: olav.engebraten@medisin.uio.no

(Received 1 March 2019, revised 26 June 2019, accepted 9 August 2019, available online 28 August 2019)

doi:10.1002/1878-0261.12561

One of the hallmarks of cancer is sustained angiogenesis. Favorable results have been reported in some breast cancer (BC) patients receiving antiangiogenic therapy with bevacizumab (Bev) in combination with chemotherapy, and further knowledge on how Bev can be optimally combined with conventional treatment to increase efficacy is strongly needed. In this randomized, neoadjuvant phase II clinical trial, 132 patients with HER2-negative, nonmetastatic BC were treated with Bev in combination with sequential chemotherapy. Biopsies were sampled before treatment, after 12 weeks with anthracycline and after taxane therapy at week 25. MicroRNA (miRNA) expression profiling was performed on biopsies from each time point. Altogether, 241 biopsies were analyzed with the aim of identifying miRNA-based biomarkers of response to therapy. Results from the miRNA analyses were reported for the ER-positive cohort, which were previously demonstrated to benefit from antiangiogenic therapy in this study. For both treatment arms of this cohort, significantly different expression was observed for 217 miRNAs between objective responding and nonresponding patients before treatment initiation. These miRNAs have been linked to regulation of epithelial-mesenchymal transition, metastasis, and tumor growth, among other processes. Bev in combination with chemotherapy resulted in similar miRNA changes to chemotherapy alone. However, the deregulation of miRNA expression occurred earlier in the Bev arm. In both arms, tumor suppressor miRNAs were found upregulated after treatment, while oncogenic miRNAs were downregulated in the Bev arm. Patients responding to Bev showed a strong correlation between deregulated miRNAs and decreased proliferation score during the course of treatment, with downregulation of miR-4465 as the strongest indicator of reduced proliferation. Integrative analyses at miRNA-, gene-, and protein expression further indicated a longitudinal decrease in proliferation. Altogether, the results indicate that proliferation

#### Abbreviations

BC, breast cancer; EMT, epithelial-mesenchymal transition; ER, estrogen receptor; FDR, false discovery rate; IPA, ingenuity pathway analysis; miRNA, microRNA; OR, objective response; OS, overall survival; pCR, pathological complete response; PFS, progression-free survival.

might represent a predictive factor for increased Bev sensitivity, which may aid in the identification of patients who could potentially benefit from Bev.

### 1. Introduction

Among women, breast cancer (BC) is the most common cancer type worldwide and the leading cause of cancer death (Bray *et al.*, 2018). The mechanisms underlying BC development are diverse and complex, with the different molecular subtypes responding differentially to chemotherapy and targeted agents (Rouzier *et al.*, 2005).

Although new and improved treatments have resulted in a more than 80% 5-year survival for BC patients, improved therapeutic strategies are still needed. Tumor angiogenesis represents one of the hallmarks in cancer, and differential expression of important mediators of this process, in particular vascular endothelial growth factor (VEGF), has been associated with tumor progression and poor prognosis in several tumor types, including BC (Berns et al., 2003; Manders et al., 2002). The anti-VEGF antibody bevacizumab (Bev) has shown increased overall survival (OS) and progression-free survival (PFS) in patients with colorectal cancer when combined with first-line chemotherapy (Hurwitz et al., 2013). In BC, treatment with Bev in combination with chemotherapy has shown less success, with variable improvements in PFS and no benefits in OS (Miles et al., 2010; Miller et al., 2007). One potential explanation for the variation in outcome may be due to differential response in different BC subtypes, as shown in two neoadjuvant clinical trials with Bey: one reported increased response rates in the triple negative BC subset (von Minckwitz et al., 2012), whereas the other reported most responding patients in the estrogen receptor (ER)-positive BC patients (Bear et al., 2012). Accordingly, there is a need for a better understanding of the underlying molecular and biological mechanisms to enable early identification of BC patients responding to neoadjuvant antiangiogenic therapy. In addition to the heterogeneity of BC defined by the different transcriptomic subtypes, microRNAs (miRNAs) have been shown to increase this complexity through their posttranscriptional regulation of gene expression (Aure et al., 2015; Aure et al., 2017).

MicroRNAs have been identified as important regulators of cellular processes (Sun *et al.*, 2010) and have been demonstrated to have both oncogenic and tumor suppressor roles in different tumor types (Kent and

Mendell, 2006; Kurozumi et al., 2017). miRNAs have also been shown to have pro-angiogenic effects (i.e., the miR-17-92 cluster (Suarez et al., 2008), miR-21 (Liu et al., 2011), and miR-378 (Lee et al., 2007)) or antiangiogenic effects (i.e., miR-221 and miR-222 (Poliseno et al., 2006)). Studies in colorectal cancer, glioblastoma, and ovarian cancer have identified miR-NAs with potential as predictors for antiangiogenic therapy by comparing expression levels in responders vs. nonresponders in surgical resections from the primary tumor before or after treatment (Chan et al., 2014; Hayes et al., 2016; Kiss et al., 2017). Changes in circulating miRNAs have also been assessed, where miR-126 has been shown to predict response in patients with metastatic colorectal cancer during chemotherapy and Bev treatment (Hansen et al., 2015). For BC, few studies have elucidated the role of miRNAs in response to Bev response. One report indicates that low expression of miR-20a-5p in BC patients is associated with response to Bev (Gampenrieder et al., 2017), but to our knowledge, the present study is the first to describe concerted changes in miRNA expression related to Bev treatment and response in BC.

In the current study, patients with HER2-negative breast carcinomas were randomized to neoadjuvant treatment with chemotherapy either alone or in combination with Bev. miRNA expression profiles from specimens taken before, during, and at the end of 25 weeks of treatment were compared to treatment response. Furthermore, important parameters like tumor proliferation, tumor stage, intrinsic subtype of BC classification (PAM50), epithelial-to-mesenchymal transition (EMT), and relapse were analyzed with respect to miRNA expression, resulting in the identification of potential candidate miRNAs involved in treatment response.

### 2. Materials and methods

### 2.1. Patient population and study design

Patient inclusion criteria have been described previously (Silwal-Pandit *et al.*, 2017). The experiments were undertaken with the understanding and written consent of each subject. The study methodologies conformed to the standards set by the Declaration of Helsinki, and the study methodologies were approved by the local ethics committee. Briefly, patients with previously untreated, HER2-negative, large ( $\geq 2.5$  cm; stage T2, T3, or T4) mammary tumors were eligible for inclusion. A total of 138 patients were randomized 1:1 to receive either chemotherapy or chemotherapy in combination with Bev. The chemotherapy regimen in the study consisted of four cycles of FEC100 (five fluorouracil 600 mg·m<sup>-2</sup>, epirubicin 100 mg·m<sup>-2</sup>, and cyclophosphamide  $600 \text{ mg} \cdot \text{m}^{-2}$ ) every 3 weeks, followed by four cycles of docetaxel 100 mg $\cdot$ m<sup>-2</sup> every 3 weeks or 12 weekly infusions of paclitaxel  $80 \text{ mg}\cdot\text{m}^{-2}$ . Bev was administered intravenously at a dose of 10 mg·kg<sup>-1</sup> every other week or 15 mg·kg<sup>-1</sup> every third week in patients receiving paclitaxel or docetaxel, respectively. Core needle biopsies were collected before treatment (week 0), after completion of 12 weeks of treatment (week 12), and from the surgical specimen (week 25). Patients with ER-positive and ER-negative tumors were included in the study; however, only ER-positive tumors were considered in the miRNA analyses described here, as these patients were shown to have a statistical significant benefit from adding Bev to the chemotherapy (Silwal-Pandit et al., 2017). For the ER-positive tumors, miRNA expression profiles were available for 97 patients at week 0, 65 patients at week 12, and 79 patients at week 25.

### 2.2. Treatment response

According to the RECIST criteria (Eisenhauer et al., 2009), partial response (PR) is defined as more than 30 % and < 100% decrease in the sum of the longest diameter of target lesions, while objective response (OR) is either PR or complete response. Therefore, we define a nonresponder as a patient with tumor shrinkage  $\leq 30\%$ . The number of samples from each time point from objective responding patients vs. nonresponding patients was 68 vs. 22 at week 0, 44 vs. 17 at week 12, and 47 vs. 27 at week 25. For seven patients, tumor volume at week 0 could not be determined, due to a scattered response in the area of the original tumor bed. Within clustering analyses, miRNA expression was also compared against pathological complete response (pCR), which is defined according to RECIST criteria as the disappearance all invasive disease in the breast and lymph nodes.

### 2.3. miRNA expression profiling

Total RNA from the tumor samples was extracted using the TRIzol reagent (Invitrogen, Oslo, Norway), according to the manufacturer's protocol. The Agilent Human miRNA Microarray V21.0 (Agilent, Santa Clara, CA, USA;  $8 \times 60$  K) with design ID 070156 was used to profile miRNA expression. For each sample, 150 ng of RNA was amplified and hybridized on the array. Data were required to pass stringent QC parameters established by Agilent that included tests for excessive background fluorescence, excessive variation among probe sequence replicates on the array, and measures of the total gene signal on the array to assess low signal. Samples failing to meet quality standards were relabeled, hybridized to arrays, and rescanned. If a sample failed QC assessment a second time, the sample was excluded from the analysis. Scanning was performed on Agilent Scanner G2565A, and signals were extracted with FEATURE EXTRACTION v9.5 (Agilent, Santa Clara, CA, USA). Microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayex

press) under accession number E-MTAB-7634.

### 2.4. Statistical analyses

All statistical analyses were performed in R version 3.1.2 (R Core Team, 2018). For each sample, the miRNA expression values were centered to the median of the observed values. Then, all miRNAs expressed in < 80% of the samples were removed. Subsequent analyses were based on the remaining 627 expressed miR-NAs. In order to identify patient- and miRNA clusters based on miRNA expression, hierarchical clustering with average linkage and Pearson correlation distance was used. To determine the number of distinct clusters and assign samples to clusters, the Partitioning Algorithm using Recursive Thresholding (PART) (Nilsen et al., 2013) was used, using the 'clusterGenomics' package in R. Fisher's exact test was applied to assess associations between categorical clinical variables and cluster assignment. To compare miRNA expression values in two subgroups of tumors, a two-sample Wilcoxon test was used. All miRNAs with false discovery rate (FDR) < 5% according to the Benjamini-Hochberg (BH) procedure were considered as significant. All, except one sample from week 25, had both mRNA and miRNA expression values and these were used further to calculate miRNA-mRNA Pearson correlations and associated P-values. All miRNA-mRNA pairs with Bonferroni-adjusted *P*-value  $\leq 0.05$  and absolute correlation value above 0.3 were considered as significant. Gene expression data are available in the ArrayExpress database (http://www.ebi.ac.uk/arra vexpress) under accession number E-MTAB-4439.

To examine the global pattern of associations between miRNA and protein expression, protein expression was modeled as a function of powers of mRNA in-*cis* and miRNA expression (Aure *et al.*, 2015). The model allows a range of functional dependencies between miRNAs and proteins and adjusts for the effect of mRNA expression on protein expression.

Venn diagrams for comparison of overlapping miR-NAs were generated using the Venny tool (Oliveros, 2007–2015).

### 2.5. Pathway analyses

Functional annotation and pathway analysis were performed using ingenuity pathway analysis (IPA; Ingenuity Systems, Redwood City, CA, USA) on genes significantly correlated to selected miRNAs of interest. Canonical pathways enriched among the genes in each list were identified in IPA using a Fisher's exact test. Pathways with a FDR < 5% according to the Benjamini–Hochberg procedure were further considered.

### 2.6. Predicting target genes for miRNAs

TargetScan Human version 7.0 (Friedman et al., 2009; Grimson et al., 2007; Lewis et al., 2005) was employed to predict target genes for candidate miRNAs. This database uses an algorithm based on conservation criteria and was ranked as the most robust compared to several other databases in a previous study (Baek et al., 2008). Predictions were filtered for transcripts with context score no larger than -0.35, where the targets with lowest context scores represent the most confident targets. To improve reliability of the target genes predicted, a second target prediction database, DIANA-microT-CDS (Maragkakis et al., 2009; Paraskevopoulou et al., 2013) was also employed. In this algorithm, conservation is a feature and not a filter, which increases sensitivity to miRNA targets that are lineage specific. Here, low confidence targets were eliminated by filtering out targets with a total context score above or equal to 0.7. Potential targets for significantly up- and downregulated miRNAs were retrieved and matched to the actual regulation of the gene.

### 3. Results

### 3.1. Clustering of miRNA expression from pretreatment biopsies identified patient subgroups associated with treatment response

Hierarchical clustering of miRNA expression of all biopsies obtained before treatment (week 0) identified three clusters with OR separating significantly from nonresponders (non-OR; Fisher's exact test, P = 0.0096, Fig. 1A). Importantly, patients were not stratified on treatment arm in this analysis. A significant association was seen between the three clusters and PAM50 subtypes as well as proliferation score, with a trend toward association between objective responders (ORs), Luminal B (LumB) subtype, and high proliferation score (Fig. 1A). These associations observed at time point 0 were not seen at week 12 and week 25 (Fig. 1B and C); at week 12 tumors clustered with no significant associations to any of the clinical variables (Fig. 1B). Notably, at operation time at week 25 patients clustered significantly according to relapse (Fig. 1C).


Several of the miRNAs present in the five clusters in Fig. 1A seemed to consistently cluster together (Table S1) throughout the course of treatment (Fig, 1B,C, cluster colors were arbitrarily assigned). This was true for the second largest cluster in Fig. 1A (colored red in Fig. 1A–C), where 73.8% of the miRNAs were present in this cluster at all time points (Table S1). In contrast, for the largest cluster in Fig. 1A (colored turquoise in Fig. 1A), only 17% of the miRNAs were present in this cluster at all time points. Nevertheless, 89% of the miRNAs in the latter cluster clustered together at week 0 and week 25.

We performed a time course study of miRNA expression also for the patients where biopsies were available from all three time points (n = 48; Fig. S1). Only two clusters were identified in this analysis, resembling the two main clusters found in Fig. 1A. In addition to the significant association to OR and tumor stage at week 0 in this restricted set, patient clustering showed a borderline significant trend toward association to proliferation (P = 0.057) and the clustering pattern changed similarly from week 0 to week 25.

When stratifying according to treatment arm, miRNA expression profiles before treatment initiation could not identify any miRNAs with differential expression between OR and nonresponders (non-OR; BH-corrected *P*-value < 0.05).

### 3.2. Multiple cancer-associated miRNAs were deregulated in responders before treatment initiation

We then focused on the miRNAs that contributed to the clustering and the association to response in the patients from both treatment arms. Wilcoxon analysis resulted in 217 miRNAs with significant differential expression between OR (n = 68) and non-OR (n = 22) before treatment initiation (Table S2). Of these, 71 miRNAs were upregulated and 146 downregulated in



**Fig. 1.** Unsupervised hierarchical clustering of miRNA expression from all patients with biopsies before treatment (week 0; A); after 12 weeks of treatment; (B) and at the end of treatment (week 25); (C). miRNAs are shown in rows and patients in columns. Clusters were identified using the PART method (Nilsen, *et al.*, 2013) with Pearson correlation-based distance and average linkage. *P*-values for associations between identified clusters and patient clinical parameters based on Fisher's exact tests are indicated. Patients clustered significantly according to OR, proliferation, and PAM50 subtypes at week 0, while only relapse was significantly associated with patient clustering at week 25.

OR vs. the non-OR. Among the downregulated miR-NAs were members of the let-7 family (let-7f-5b, 7e-5p, 7a-5p, let-7d, let7g) and the miR-200 family

(miR-200a-3p, miR-200b-3p, and miR-429). Both of these families regulate the expression of multiple genes related to EMT and metastasis (Ding, 2014). In

addition, miRNAs known as tumor suppressors, like miR-125a/b (Yan *et al.*, 2018), and onco-mirs, like miR-21 (Yan *et al.*, 2011), were also found significantly downregulated in ORs at week 0 compared to non-ORs.


Interestingly, 55 of the 71 (77.5%) upregulated miR-NAs had nomenclature numbers > 3000. Only eight out of the 146 downregulated miRNAs (5.5%) had similar high numbers. According to the miRNA annotation criteria (Ambros *et al.*, 2003), the miRNA identifying numbers are assigned sequentially according to discovery. Thus, the biological functions of miRNAs with high nomenclature are less characterized and studied due to their more recent discovery.

# 3.3. Treatment-induced changes in miRNA expression over time are linked to decreased proliferation and increased chemotherapy sensitization, with a stronger effect in the bevacizumab arm

We then looked at the numbers of significantly differexpressed miRNAs (BH-corrected entially *P*value < 0.05) between time points, that is, from treatment initiation (week 0) until time of operation (week 25) in each treatment arm. A larger number of miR-NAs were deregulated in the chemotherapy arm (n = 251 miRNAs) compared to the Bev arm (n = 139)miRNAs; Fig. 2A,B and Table S3A,B, respectively), regardless of treatment response. However, the two treatment arms differed in the time interval wherein the greater change in expression occurred. While in the Bev arm, a larger number of deregulated miRNAs were observed already at the early interval, a higher

number of miRNAs were deregulated at the later interval in the chemotherapy arm. In the biopsies from the patients in the Bev arm, we found 76 miRNAs changing from week 0 to week 12, compared to no miRNAs at the later interval (week 12-week 25), while in the chemotherapy arm there were 98 miRNAs that changed significantly between week 12 and 25, compared to no miRNAs at the early time interval. We were interested in whether the change in miRNA expression in the Bev arm could be explained by Bev having a chemotherapy-enhancing effect, or whether Bev elicits molecular effects on the miRNA expression that differ from those induced by chemotherapy. Therefore, the 139 differentially expressed miRNAs from week 0 to week 25 in the Bev arm were compared to the 251 differentially expressed miRNAs from week 0 to week 25 in the chemotherapy arm. As illustrated in Fig. 2C and Table S3C, 126 miRNAs were found overlapping between the two treatment arms across the treatment weeks, regardless of response to therapy. All of these were regulated in the same direction in both treatment arms; 120 miRNAs were upregulated and 6 miRNAs downregulated. Interestingly, several of the miRNAs with > 3-fold upregulation in both treatment arms from week 0 to week 25 (Table 1) such as miR-100-5p and miR-125b are known to inhibit proliferation, migration, and invasion in BC cell lines and tissue (Gong et al., 2015; Li et al., 2018). Furthermore, several of these miRNAs such as miR-328 and miR-195 have been reported to sensitize breast tumors to chemotherapy (Pan et al., 2009; Yang et al., 2013).

In contrast to the most upregulated miRNAs found in patients from both treatment arms, all but one of



**Fig. 2.** Changes in miRNA expression over time, regardless of treatment response, within (A) the chemotherapy arm and (B) the Bev arm. (C) 126 miRNAs were found differentially expressed in both treatment arms from week 0 to week 25, while 125 miRNAs were exclusively differentially expressed in the chemotherapy arm. Thirteen miRNAs were differentially expressed only in the Bev arm.

Table 1. Differentially expressed miRNAs from week 0 to week 25 with more than threefold upregulation in both treatment arms and with demonstrated roles in BC tissue and cell lines.

miRNAª	Functional role	Identified target gene	Reference
miR-99a-5p	Suppress proliferation and migration	IGF-1R	Xia <i>et al.</i> (2016)
miR-125b-5p/ miR-125b-2-3p	Inhibits BC proliferation, migration, and invasion/ regulates cisplatin resistance in BC.	KIAA1522/HAX1	Hui <i>et al</i> . (2018), Li <i>et al.</i> (2013)
miR-187-5p	Increases aggressiveness and invasion		Mulrane <i>et al.</i> (2012), Mandujano- Tinoco <i>et al.</i> (2017)
miR-100-5p	Suppress proliferation, migration, and invasion	FZD-8 and Wnt/β-catenin pathway	Gong <i>et al.</i> (2015), Jiang <i>et al.</i> (2016)
miR-143-3p/5p	Inhibits invasion and proliferation, induces hypermethylation	DNMT3A	Ng <i>et al.</i> (2014), Johannessen <i>et al.</i> (2017)
miR-377-3p	Lower expression in HER2+ vs. HER2- BC		Leivonen <i>et al.</i> (2014)
miR-195-3p/5p	Inhibits proliferation, invasion, metastasis, and angiogenesis/ Increases adriamycin sensitivity	FASN, HMGCR, ACACA, CYP27B1, IRS1, Raf-1	Yang <i>et al.</i> (2013), Singh <i>et al.</i> (2015) Wang <i>et al.</i> (2016)
miR-328-5p	Inhibits proliferation and increases drug sensitivity	RAGE, BCRP	Pan <i>et al.</i> (2009), Luo <i>et al.</i> (2018)
miR-497-5p	Inhibits growth, migration, invasion, and EMT	Cyclin E1, Raf-1, Ccnd1, Slug	Li <i>et al.</i> (2011), Luo <i>et al.</i> (2013), Wu <i>et al.</i> (2016)
miR-376a/c-3p	Inhibits growth	NRP-1	Zhang <i>et al.</i> (2018)
miR-145-5p	Inhibits proliferation and migration	TGF-β1, FSCN-1	Zhao <i>et al.</i> (2016), Ding <i>et al.</i> (2017)
miR-381-3p	Inhibits proliferation, cell cycle progression, and migration/increases doxorubicin sensitivity	SETDB1, FYN	Mi <i>et al.</i> (2018), Wu <i>et al.</i> (2018)
miR-4472	Downregulated in chemoresistant BC tissue		Wang <i>et al.</i> (2018b)

<sup>a</sup>BH-adjusted *P*-values  $\leq$  0.05.

the 13 miRNAs (miR-125a-3p) that changed from week 0 to week 25 exclusively in the Bev arm were downregulated (Table 2). Importantly, the majority of the downregulated miRNAs have been identified as oncogenic miRNAs, while the upregulated miR-125a-3p has been identified as a tumor suppressor in several cancer forms, including BC (Alzrigat and Jernberg-Wiklund, 2017; Xu et al., 2016).

Altogether increased expression of tumor suppressor miRNAs in both treatment arms, while downregulated oncogenic miRNAs in the Bev arm could indicate a general suppression of tumor proliferation and

Table 2. Differentially expressed miRNAs from week 0 to week 25 found exclusively in the bevacizumab arm.

miRNAª	Fold change	Functional role	Identified target gene	Reference
miR-183-5p	0.28	Promotes proliferation and migration		Li <i>et al.</i> (2014) Macedo <i>et al.</i> (2017)
miR-1307-5p	0.45	Regulates cisplatin resistance in BC	MDM4	Wang and Zhu (2018)
miR-1260a	0.51	Unknown in BC		
miR-200c-3p	0.53	Suppression of BC migration, invasion, and metastasis	FHOD1, PPM1F, Foxf2	Jurmeister <i>et al.</i> (2012), Zhang <i>et al.</i> (2017)
miR-181c-3p	0.54	Promotes proliferation	PTEN	Zhang and Zhang (2015)
miR-1181	0.63	Inhibits invasion and proliferation in pancreatic cancer	STAT3	Wang <i>et al.</i> (2017)
miR-7977	0.67	Unknown in cancer		
miR-181b-5p	0.67	Promotes EMT and chemoresistance in BC	YWHAG, Bim	Yoo <i>et al.</i> (2016) Zheng <i>et al.</i> (2016)
miR-1260b	0.71	Overexpression in prostate cancer		Said <i>et al.</i> (2018)
miR-93-5p	0.72	Increases chemotherapy resistance	Bcl-2, P-gp, PTEN	Chu <i>et al.</i> (2017), Li <i>et al.</i> (2017), Wang <i>et al.</i> (2018a)
miR-4261	0.74	Increases proliferation and migration of CRC	MCC	Jiao <i>et al.</i> (2017)
miR-106b-5p	0.79	Increases chemotherapy resistance	PTEN, SMAD7, EP300	Hu <i>et al.</i> (2016), Li <i>et al.</i> (2017)
miR-125a-3p	1.33	Tumor suppressor and potentiates chemotherapy resistance	HuR, BAP1	Guo <i>et al.</i> (2009), Xu <i>et al.</i> (2016), Yan <i>et al.</i> (2018)

<sup>a</sup>BH-adjusted *P*-values  $\leq$  0.05.

increased sensitivity to chemotherapy over time within the tumors receiving Bev treatment.

We also analyzed the number of significantly differentially expressed miRNAs between time points in each treatment arm only within patients from who we had obtained biopsies from all three time points (regardless of response status). This included 23 ORs and 5 non-ORs in the chemotherapy arm, and 11 ORs and 7 non-ORs in the Bev treatment arm. However, none of the miRNAs significantly changed expression over time after BH correction for multiple testing in either of the two treatment arms (data not shown).

### 3.4. miRNAs are highly correlated to histone H3 protein expression throughout treatment


By combining miRNA expression with mRNA and protein expression, we next attempted to acquire a more integrated and global view of the regulatory circuits that formed in result of the treatment. We therefore combined the expression data from three molecular platforms at three time points in order to gain insight into the combined effect of miRNA and mRNA expression on protein expression over time. To achieve that, protein expression was modeled as a function of mRNA and miRNA expression in a bivariate regression model for each miRNA as described previously (Aure et al., 2015). The model was applied to mRNA and protein expression for 210 selected cancer-associated genes and the 627 miRNAs studied here. The effect of one miRNA at a time was considered, for all three time points. These analyses were performed for all patients together across treatment arms and response groups. From these analyses, a beta value (indicating the association between a miRNA and a protein) was computed for each time point for all combinations of miRNAs and proteins. From these analyses, significant changes in miRNA expression were seen over time. Interestingly, almost all significantly changing miRNAs were correlated to H3 histone family member 3 (histone H3) across the treatment course (Fig. 3A,B).

Histone H3 was not found differentially expressed in responding patients in either of the two treatment arms from week 0 to week 25, supporting the stable expression of this gene throughout the treatment. Furthermore, as seen in Fig. 3B and Table S4, the number of proteins involved in miRNA–protein association increased from three proteins correlating to 134 miR-NAs (histone H3, RBM15, and caspase 6) at week 0 to 63 proteins correlating to 120 miRNAs at week 25. This suggests a broad shift in miRNA–protein correlations throughout the treatment course.

# 3.5. Differentially expressed miRNAs in bevacizumab-responding patients correlate with proliferation

To see whether the significantly differentially expressed miRNAs in the two treatment arms were linked to treatment response, the patients from each treatment arm were further split into OR vs. nonresponders (non-OR) and differentially expressed miRNAs were identified between week 0 and 25.

A total of 194 miRNAs were differentially expressed in the responding patients who were given chemotherapy only (Fig. 4A and Table S5A), while only 59 miR-NAs were found significantly differentially expressed from week 0 to week 25 in the responders who



**Fig. 3.** (A) miRNA–mRNA–protein integration model showing the miRNA–protein associations being kept most constant over time. On the x- and y-axis, the beta value is plotted for a miRNA–protein pair at week 0 (x-axis) and week 25 (y-axis). (B) Venn diagram showing the proteins with most associations to miRNAs at each time point. Percentage indicates the number of associated miRNAs to each protein within the total number of significant miRNA–protein associations. Histone H3 ranked highest with most associations at all three time points.




Fig. 4. Significant changes in miRNA expression over time in responding patients only within (A) the chemotherapy arm and (B) the Bev arm. (C) 54 miRNAs were found overlapping in the two treatment arms from week 0 to week 25, while 140 miRNAs were found exclusively in the chemotherapy arm. (D) The five miRNAs found exclusively in the Bev arm.

received Bev in addition (Fig. 4B and Table S5B). As expected, all the 54 overlapping miRNAs found differentially expressed in responders in both treatment arms (Fig. 4C and Table S5C) were also found among the 126 overlapping miRNAs in Fig. 2C, the latter which assessed miRNA expression changes regardless of treatment response.

As previously shown in Silwal-Pandit et al. (2017) and Hoglander et al. (2018), Bev treatment was most effective in patients with highly proliferating tumors. Therefore, the differentially expressed miRNAs between OR vs. non-OR in each treatment arm were correlated to a proliferation score (Parker et al., 2009). Of the 59 differentially regulated miRNAs from week 0 to week 25 in the Bev arm, 44 were significantly correlated to the proliferation score (Bonferroni-corrected *P* value < 0.05 and absolute Pearson correlation  $\ge$  0.3) when summarizing all the ER-positive patients from all time points (Table S6). However, when looking at each time point separately, only eight miRNAs listed in Table 3 were found significantly correlated at week 0. Of these, six miRNAs were significantly negative, while two miRNAs were significantly positive correlated to the proliferation score. Interestingly, the two positive correlating miRNAs were among the five downregulated miRNAs in the Bev arm, suggesting a potential decrease in proliferation in Bev-responding tumors from week 0 to week 25. Furthermore, miR-4465, together with miR-195-3p, were the only two miRNAs among the 59 Bev-associated subset that were significantly correlating to proliferation at week 12, while none were kept significant at week 25 (Table S6). In the chemotherapy arm, 26 of the 140 miRNAs correlated significantly (Bonferroni-corrected P value < 0.05 and absolute Pearson correlation  $\ge 0.3$ ) to proliferation across all time points, while 28 miR-NAs were found significant at week 0 and none at weeks 12 and 25 (data not shown).

To validate the correlation of expressed miRNAs to proliferation, miRNA expression from an independent BC cohort (Nik-Zainal *et al.*, 2016) was used. In this cohort, proliferation scores were not available; thus, the total number of mitoses in the ER-positive samples was used as a proxy. Only miRNAs with significant correlation to proliferation in the present dataset were tested. As seen in Table 2, only miR-4465 showed a significant correlation (Pearson's r = 0.3), of the Bevassociated miRNAs at week 0. Furthermore, as in the NeoAva dataset, this correlation was positive. In the chemotherapy arm, none of the 140 miRNAs had a Pearson correlation value  $\geq 0.3$  in the validation dataset (data not shown).

# 3.6. Bevacizumab-specific miRNAs correlate to cell cycle regulation, transcriptional regulation, and leukocyte extravasation

The five miRNAs found exclusively differentially expressed in responding patients in the Bev arm (Fig. 4D) were correlated to the mRNA expression of all genes in the same tumors. This gave rise to 5409 significant correlations (Bonferroni-corrected *P*-value < 0.05) with an absolute correlation value  $\geq 0.3$  (Table S7). From these, the highest number of correlations was to miR-4449, miR-4465, miR-141-3p, and miR-1181 [n = 2892 (37.5 %), n = 1271 (33 %),

 
 Table 3. Significantly deregulated miRNAs in bevacizumabresponding patients and their correlation to proliferation at week 0.

	NeoAva		Nik-Zainal <i>et al</i> .	
miRNA	Correlation <sup>a</sup>	<i>P</i> -value <sup>b</sup>	Correlation <sup>a</sup>	<i>P</i> -value <sup>b</sup>
miR-145-5p	-0.53	1.65E-06	-0.21	1.13E-01
miR-99a-5p	-0.48	4.33E-05	-0.24	2.55E-02
miR-4324	-0.47	5.95E-05	-0.15	1.00E+00
miR-125b-2-3p	-0.47	6.63E-05	-0.12	1.00E+00
miR-100-5p	-0.45	1.72E-04	-0.23	3.99E-02
miR-125b-5p	-0.45	2.06E-04	-0.18	4.61E-01
miR-1181	0.46	1.32E-04	0.21	8.74E-02
miR-4465	0.46	1.24E-04	0.33	5.22E-05

<sup>a</sup>Pearson correlation.

<sup>b</sup>BH-adjusted *P*-values  $\leq$  0.05.

n = 998 (24 %), and n = 246 (5.7 %), respectively], whereas only two transcripts were found significantly correlated to miR-1307-5p. The significantly correlating genes to each of the five miRNAs were analyzed for signaling pathway enrichment through IPA. The top 10 most significant pathways linked to these mRNAs were enriched for three main biological

functions; mRNAs correlating to miR-4465 and miR-1181 were highly associated with cell cycle regulation and control and DNA damage response and repair. miR-4495 was associated with growth factor receptor signaling, like VEGF and HER2/HER3, in addition to DNA damage responses like the nucleotide excision repair pathway (Fig. 5 and Table S8). To confirm that the correlating mRNAs were in fact also significantly deregulated in the tumors, Wilcoxon tests were performed using mRNA expression from responding tumors at week 0 vs. week 25 in each treatment arm. From these analyses, we found 3980 significantly deregulated genes (BH-corrected P < 0.05) in the Bev arm (Table S9A) and 4469 deregulated genes in the chemotherapy arm (Table S9B). To investigate whether the significantly correlating genes to each of the five Bev-associated miRNAs were also predicted target genes, TargetScan and microT-CDS were employed. As indicated in Table S6, miR-141-3p, miR-4465, and miR-4449 showed the highest number of correlations to genes that were also predicted targets through either one of the two prediction databases.




Fig. 5. The 10 most significantly associated pathways associated with mRNAs with a significant correlation to four of the five miRNAs found differentially expressed between week 0 and week 25 in Bev-responding patients.

miR-141-3p was associated with leukocyte extravasation (diapedesis) both within granulocytes (neutrophils, basophils, and eosinophils) and agranulocytes (monocytes and lymphocytes), in addition to migration- and adhesion-associated processes like Ephrin receptor signaling and Actin Nucleation By ARP-WASP Complex. An interesting predicted target with negative correlation to miR-141-3p was *CXCL12* (*SDF-1*), due to its immune-associated processes. Gene expression analyses confirmed a significant upregulation of *CXCL12* in objective responding tumors from week 0 to week 25, supporting the potential targeting effect of miR-141-3p on this gene.

The majority of correlating and predicted target genes for miR-141-3p were involved in DNA binding and transcriptional regulation, like ETS transcription factor (*ERG*), H2A histone family member Z (*H2AFZ*), six homeobox 4 (*SIX4*) signal transducer, and activator of transcription 5B (*STAT5B*) and zinc

finger protein 281 (*ZNF281*). This was in line with the pathway 'DNA methylation and transcriptional repression signaling' as one of the most significant pathways associated with miR-141-3p. Importantly, and in contrast to the other four Bev-specific miRNAs, none of the pathways linked to miR-141-3p passed multiple testing correction (Table S7).

As illustrated in Table 4, many of the correlating and predicted target genes of miR-4465 were also involved in transcriptional regulation and epigenetically modification of chromatin, including members of the Polycomb group (PcG) proteins, like *EPC1* and *EZH2*. Of special interest was the correlation between miR-4465 and both *EZH2* and *HMGA1*, as both of these genes were among the genes with highest correlation score, in addition to being predicted targets with high target score in both prediction databases employed. Both of these genes, together with *E2F7* and *HOXA5*, play important roles in regulating gene transcription. Importantly, due to their

 Table 4.
 miR-4465 correlating genes with both predicted target scores and significant regulation in bevacizumab-responding patients from week 0 to week 25.

mRNA	Gene name	Correlation to miR-4465ª	mRNA fold change in bev-arm W0 to W25 <sup>b</sup>
BID	BH3 interacting domain death agonist	0.46	0.73
PNRC1	Proline-rich nuclear receptor coactivator 1	-0.35	1.65
C20orf24	Chromosome 20 open reading frame 24	0.48	0.75
HMGA1	High-mobility group AT-hook 1	0.38	0.49
EZH2	Enhancer of zeste 2 polycomb repressive complex 2 subunit	0.45	0.38
MEMO1	Mediator of cell motility 1	0.44	0.82
TTC13	Tetratricopeptide repeat domain 13	0.34	0.76
ARPC3	Actin-related protein 2/3 complex, subunit 3, 21kDa	0.38	0.75
KPNA2	Karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	0.47	0.53
EPC1	Enhancer of polycomb homolog 1 (Drosophila)	-0.34	1.35
HOXA5	Homeobox A5	-0.37	2.13
FLVCR1	Feline leukemia virus subgroup C cellular receptor 1	0.38	0.59
FAM172A	Family with sequence similarity 172, member A	-0.47	1.45
CCDC28A	Coiled-coil domain containing 28A	-0.35	1.26
DEPDC1B	DEP domain containing 1B	0.49	0.68
E2F7	E2F transcription factor 7	0.46	0.56
CKS2	CDC28 protein kinase regulatory subunit 2	0.45	0.33
UCK2	Uridine-cytidine kinase 2	0.39	0.72
ZNF598	Zinc finger protein 598	0.37	0.80
INTU	Inturned planar cell polarity protein	-0.40	1.45
ARMCX4	Armadillo repeat containing, X-linked 4	-0.36	1.81
PHF21A	PHD finger protein 21A	-0.44	1.35
PELI2	Pellino E3 ubiquitin protein ligase family member 2	-0.39	2.05
FAM49B	Family with sequence similarity 49, member B	0.44	0.61
IL2RA	Interleukin 2 receptor, alpha	0.32	0.80
DEPDC1	DEP domain containing 1	0.47	0.63

<sup>a</sup>Pearson correlation and Bonferroni-adjusted *P*-value  $\leq 0.05$ 

<sup>b</sup>BH-adjusted *P*-values  $\leq$  0.05.

positive correlation, a direct targeting of miR-4465 on these transcripts cannot be assumed.

Interestingly, correlation was found between miR-4449 and the predicted target gene *ERG*, which besides regulating cell proliferation and differentiation, also plays a crucial role in promoting angiogenesis and vascular stability (Birdsey *et al.*, 2015; Shah *et al.*, 2017). This was in line with the association between this miRNA and the pathway 'VEGF family ligand-receptor interactions' when assessing pathway enrichment of correlated genes.

Altogether, among the correlating and predicted targets of the five Bev-associated genes, many seem to be linked to DNA binding and transcriptional regulation.

### 4. Discussion

MicroRNAs have emerged as regulators for a range of cellular events like proliferation, differentiation, apoptosis, and metabolism. Studies have demonstrated a role for miRNAs in resistance or sensitization of tumors to chemotherapy and radiotherapy. Previous studies have looked at miRNA's role as predictors for antiangiogenic therapy by comparing their expression in responders vs. nonresponders either before or after treatment (Kiss *et al.*, 2017), or changes in the level of circulating miR-NAs (Hansen *et al.*, 2015). The present study is, to our knowledge, the first study to address the changes in miRNA expression within the tumor over the course of treatment, and their correlation to response.

Here, we show that neoadjuvant addition of Bev to chemotherapy in HER2-negative, ER-positive BC tumors elicits many of the same molecular changes as chemotherapy alone. However, the changes occur earlier in the treatment course, compared to the chemotherapy arm. Previous studies have shown that Bev promotes a more homogenous intratumor distribution of paclitaxel, thereby improving the antitumor response (Cesca et al., 2016). Based on these reports, we hypothesize that the addition of Bev to chemotherapy elicits a faster chemotherapeutic tumor response at the molecular level, but that the final net change within treatment arms would perhaps be the same. This could potentially explain the documented increase in PFS when combining Bev with standard chemotherapy in many clinical trials, but a lack of OS benefit (Montero et al., 2012). Importantly, for both treatment arms chemotherapy was switched from FEC100 to taxanes from week 12 to week 25, making it harder to directly compare the two different time periods. We therefore chose to compare biopsies from before treatment initiation with samples taken at time of surgery within the two treatment arms. Regardless of response,

we found that a large proportion of the differentially expressed miRNAs from week 0 to week 25 within the two treatment arms were overlapping; a finding which supports our hypothesis of Bev potentiating the chemotherapeutic effect. Furthermore, both the 126 overlapping miRNAs found in both treatment arms and the 13 deregulated Bev-specific miRNAs from week 0 to week 25, were associated with general suppression of tumor proliferation, and increased sensitivity to chemotherapy. The association toward sensitizing the cells to chemotherapy also supports the hypothesis of Bev exerting its effect through potentiating the effect of the chemotherapeutic drug.

Clustering of miRNA expression before treatment initiation separated the patients according to objective tumor response, proliferation, and PAM50 subtypes. The change in patient clustering and loss of association to clinical parameters from week 0 to week 25 indicates a change in miRNA expression as the tumor evolves or responds to therapy. The loss of association to response and proliferation could be explained by the gradual shift of tumors becoming more normallike, as shown in the heatmaps of week 25 and in the previous gene expression analyses (Silwal-Pandit *et al.*, 2017).

The latter study also showed that patients with highly proliferating tumors and basal-like subtype responded better to therapy, and that proliferation score was more strongly suppressed in the combination therapy arm. In line with this, we found a correlation between the two Bev-specific miRNAs miR-4465 and miR-1181 and proliferation scores, wherein the former was verified in another clinical BC dataset. Whether the downregulation of miR-4465 over time merely reflects a loss of the most proliferating tumor cells during the course of treatment, or whether a direct or indirect mechanism between this miRNA and proliferation exists needs further studies. As miR-4465 is newly introduced into the Agilent microarray platform, we did not find additional clinical cohorts with matching conditions to verify the findings. However, few patients in the The Cancer Genome Atlas cohort expressed this miRNA (data not shown), which could suggest that miR-4465 reflects a cell type-specific miRNA.

To gain insight into the combined effect of miRNA and mRNA expression on protein expression over time, protein expression was modeled as a function of miRNA and mRNA expression. Although these analyses are limited to only 210 proteins, the model could highlight some important associations between miRNA expression and gene/protein expression. In these analyses, we found that most miRNAs were associated with histone H3 at all three time points. However, in contrast to week 0 and week 12 wherein almost all expressed miRNAs were linked to this protein, tumors from week 25 showed a greater diversity between miRNAs correlating to a larger set of proteins. Histone H3 represents a replication-independent histone gene and has been implicated in the epigenetic regulation of diverse biological processes. Incorporation of histone H3 into a nucleosome has shown to accumulate modifications associated with gene activation or open chromatin (Loyola and Almouzni, 2007; McKittrick et al., 2004). Furthermore, histone H3-null mice embryos show reduced cell proliferation and increased cell death (Jang et al., 2015), and its phosphorylated form (phospho-histone H3) has been suggested to better represent proliferation than Ki67 (Kim et al., 2017). The gradual loss of miRNA correlations to this protein from week 0 to week 25 supports the observed decrease in proliferating tumor cells in the gene expression analyses from the same patients. The concordance between the gene expression analyses and the miRNA results indicates that miRNAs could have the potential to function as predictors of general treatment response.

We found five deregulated Bev-specific miRNAs that showed a general high correlation to cell cycle and transcriptional regulation. Interestingly, there was a significant enrichment among positively correlating genes for miR-4465 involved in chromatin- and transcriptional regulation, like histone cluster 1 and 2 family members and E2F genes, as well as cell cycle-related pathways, like cell division cycle- and cyclin-dependent genes. Many of the histone family members associated with miR-4465 are replication-dependent histones, which are expressed during S-phase end in a conserved stem-loop rather than a polyA tail. Downregulation of these genes indicates a suppression of cell cycle progression. miR-4465 is not confidently annotated but shares seed with the confidently annotated miR-26-5p. High-mobility group AT-hook 1 (HMGA1) and enhancer of zeste 2 (EZH2) polycomb repressive complex 2 (PRC2) were the only genes predicted as miR-4465 targets in both target prediction databases employed, with high prediction scores and which showed significant changes in gene expression from week 0 to week 25. EZH2 is a histone methyltransferase subunit in PRC2, which mediates transcriptional repression through histone methylation (Yoo and Hennighausen, 2012). HMGA1 functions as a regulator of chromatin structure and gene transcription that can transactivate promoters and thereby drive gene expression in response to extracellular and intracellular signals (Reeves, 2001; Thanos and Maniatis, 1995). Both genes have been found upregulated in several tumors and have been

associated with a myriad of fundamental cellular processes, like cell cycle progression, differentiation, apoptosis, and DNA repair (Chen et al., 2012; Esposito et al., 2010; Giannini et al., 2000; Mao et al., 2009; Pawlyn et al., 2016; Schuldenfrei et al., 2011; Ueda et al., 2007; Wu et al., 2011; Zhang et al., 2014). Both miR-4465 and miR-26-5p have been shown to suppress tumor proliferation and metastasis in several cancers by directly targeting EZH2 and HMGA1 (Lin et al., 2013; Sun et al., 2017; Zhou et al., 2017). However, the positive correlation between miR-4465 and both EZH2 and HMGA1 in this study, also reflected through the downregulation of both the miRNA and genes, contradicts the general belief of miRNAs as inhibitors of gene expression. The positive correlation found here is potentially the result of other regulatory mechanisms, as EZH2 and HMGA1 are regulated through several other mechanisms.

The additional finding of miR-141-3p correlating to lymphocyte extravasation is in line with previous findings on gene expression (Silwal-Pandit et al., 2017) and serum cytokines (Jabeen et al., 2018), demonstrating high expression of immune-related genes in patients with pCR to Bev. Importantly, in the latter study ER-positive and ER-negative tumors were combined when analyzing patients with pCR vs. non-pCR. When we performed miR-141-3p correlation to all mRNAs within both ER-positive and ER-negative patients, we also found a strong and significant link to several immune-related processes (data not shown). These results may indicate that miR-141-3p may play a larger role in the ER-negative subset of patients, in line with a higher frequency of tumor infiltrating lymphocytes in ER-negative vs. ER-positive tumors (Hammerl et al., 2018). Nevertheless, the significant anticorrelation between miR-141-3p and CXCL12 (SDF-1), as well as the latter being a predicted target for this miRNA, does suggest immunological effects from this miRNA in the ER-positive subset of patients responding to Bev as well. The significant anticorrelation found here has also been validated in other studies (Periyasamy-Thandavan et al., 2018). The association between the antiangiogenic drug Bev and the downregulation of miR-141-3p is also interesting, as CXCL12 and its receptor CXCR4 has been identified as critical mediators for ischemia-specific recruitcirculating ment of progenitor cells for neovascularization (Ho et al., 2010). In addition, CXCL12 has been shown to be angiogenic in various tumors (Koshiba et al., 2000; Kryczek et al., 2005). Of note, miR-141-3p has been found to be expressed in mammary epithelial cells themselves (McCall et al., 2017).

### 5. Conclusion

In this study, we have demonstrated a difference in miRNA expression between OR and nonresponders at diagnosis (Fisher's exact test, P = 0.0096). Notably, after the neoadjuvant treatment (at week 25), patients clustered significantly according to relapse, revealing a set of miRNAs in a tumor sample at operation after treatment that may indicate relapse. In this longitudinal study, the results based on repeated tumor sampling indicate a treatment-induced deregulation of several miRNAs associated with tumor suppression in responding patients. This was found in both treatment arms over time; however, the earlier change in the combination arm indicates that Bev adds to the effect of the chemotherapeutic drug. Furthermore, the association between Bev-specific miRNAs and genes involved in proliferation, cell cycle regulation transcriptional control supports an additive effect of antiangiogenic treatment to the more aggressive tumors. The enrichment of immune-related processes associated with miR-141-3p supports our gene expression data, and the potential role of Bev in promoting response in immune activated tumors. Finally, the results demonstrate that miRNA expression analyses add an important layer of information to the understanding of molecular functions in response to antiangiogenic therapy.

### Acknowledgements

This research was supported by funds from the Norwegian Cancer Society (Project no. 419628, 138296 and 198091) and South Eastern Norway Health Authority (Project no. 2014021 and 2019081). The clinical study and the data processing were funded in part by generous grants from the Pink Ribbon Movement and Norwegian Breast Cancer Society (Project no. 11003001), and the Norwegian Research Council (Project no. 191436/ V50). We greatly acknowledge all the participating patients in this study, and Tone Olsen for her expertise and help in running the miRNA arrays.

### **Conflict of interest**

The study was cosponsored by Roche Norway and Sanofi-Aventis, contributing to the funding of the clinical study. No other potential conflicts of interest were disclosed among the authors.

### Data availability

Data from the miRNA microarray analyses performed in this study are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-7634. Additional gene expression data from the same clinical study are also available in the ArrayExpress database under accession number E-MTAB-4439.

### Author contributions

OE and ALBD designed the study. EML, MRA, OCL, DN, and MHH performed the computations and statistical analyses. EML ran the Agilent miRNA arrays and wrote the paper with input from all authors.

### References

- Alzrigat M and Jernberg-Wiklund H (2017) The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma. *RNA Dis* **4**, e1529.
- Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M *et al.* (2003) A uniform system for microRNA annotation. *RNA* 9, 277–279.
- Aure MR, Jernstrom S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R;Oslo Breast Cancer Research Consortium (OSBREAC), Ram P and Lu Y *et al.* (2015) Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. *Genome Med* 7, 21.
- Aure MR, Vitelli V, Jernstrom S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen S-K, Vollan HKM, Lüders T *et al.* (2017) Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. *Breast Cancer Res* 19, 44.
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP and Bartel DP (2008) The impact of microRNAs on protein output. *Nature* 455, 64–71.
- Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L *et al.* (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med* 366, 310–320.
- Berns EM, Klijn JG, Look MP,Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME *et al.* (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. *Clin Cancer Res* 9, 1253–1258.
- Birdsey GM, Shah AV, Dufton N, Reynolds LE, Osuna Almagro L, Yang Y, Aspalter IM, Khan ST, Mason JC, Dejana E *et al.* (2015) The endothelial transcription factor ERG promotes vascular stability

and growth through Wnt/beta-catenin signaling. *Dev Cell* **32**, 82–96.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68, 394–424

Cesca M, Morosi L, Berndt A, Nerini IF, Frapolli R, Richter P, Decio A, Dirsch O, Micotti E, Giordano S *et al.* (2016) Bevacizumab-induced inhibition of angiogenesis promotes a more homogeneous intratumoral distribution of paclitaxel, improving the antitumor response. *Mol Cancer Ther* **15**, 125–135.

Chan JK, Kiet TK, Blansit K, Ramasubbaiah R, Hilton JF, Kapp DS and Matei D (2014) MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. *Gynecol Oncol* **133**, 568–574.

Chen YH, Hung MC and Li LY (2012) EZH2: a pivotal regulator in controlling cell differentiation. *Am J Transl Res* **4**, 364–375.

Chu SH, Liu G, Xia PX, Chen GQ, Shi F, Yi T and Zhou HY (2017) miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer. *Oncol Rep* 38, 2401–2407.

Ding XM (2014) MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). *Chin J Cancer* **33**, 140–147.

Ding YL, Zhang CF, Zhang JH, Zhang N, Li T, Fang J, Zhang Y, Zuo F, Tao Z, Tang S *et al.* (2017) miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-beta 1 expression. *Int J Oncol* **50**, 1701–1710.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M *et al.* (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* **45**, 228–247.

Esposito F, Tornincasa M, Chieffi P, De Martino I, Pierantoni GM and Fusco A (2010) High-mobility group A1 proteins regulate p53-mediated transcription of Bcl-2 gene. *Can Res* **70**, 5379–5388.

Friedman RC, Farh KK, Burge CB and Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res* **19**, 92–105.

Gampenrieder SPP, Rinnerthaler G, Hackl H, Steiner M, Monzo Fuentes C, Hufnagl C, Hauser-Kronberger C, Egle A and Greil R (2017) 92PLow expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial. *Ann Oncol* 28(suppl\_5), mdx363.008.

Giannini G, Kim CJ, Di Marcotullio L, Cardinali B, Cerignoli F, Ristori E, Zani M, Frati L, Screpanti I and Gulino A. (2000) Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. *Brit J Cancer* **83**, 1503–1509.

- Gong Y, He T, Yang L, Yang G, Chen Y and Zhang X (2015) The role of miR-100 in regulating apoptosis of breast cancer cells. *Sci Rep* **5**, 11650.
- Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP and Bartel DP (2007) MicroRNA targeting specificity in mammals: determinants beyond seed pairing. *Mol Cell* 27, 91–105.

Guo X, Wu YH and Hartley RS (2009) MicroRNA-125a represses cell growth by targeting HuR in breast cancer. *RNA Biol* **6**, 575–583.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM and Debets R (2018) Breast cancer genomics and immuno-oncological markers to guide immune therapies. *Semin Cancer Biol* 52, 178–188.

Hansen TF, Carlsen AL, Heegaard NHH, Sorensen FB and Jakobsen A (2015) Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. *Br J Cancer* 112, 624–629.

- Hayes J, Thygesen H, Gregory W, Westhead DR, French PJ, Van Den Bent MJ, Lawler SE and Short SC (2016) A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. *Mol Oncol* 10, 1296–1304.
- Ho TK, Tsui J, Xu SW, Leoni P, Abraham DJ and Baker DM (2010) Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR27 in human critical leg ischemia. *J Vasc Surg* **51**, 689– 699.
- Hoglander EK, Nord S, Wedge DC, Lingjærde OC, Silwal-Pandit L, Gythfeldt HL, Vollan HKM, Fleischer T, Krohn M, Schlitchting E *et al.* (2018) Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations. *Genome Med* 10, 92.
- Hu YH, Li KY, Asaduzzaman M, Cuella R, Shi H, Raguz S, Coombes RC, Zhou Y and Yague E (2016) miR-106b similar to 25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep 35, 1170–1178.
- Hui GN, Zhao XK, Wang J, Lv LT, Wang CQ, Feng L, Shen LQ and Ren WL (2018) miR-125b regulates the drug-resistance of breast cancer cells to doxorubicin by targeting HAX-1. Oncol Lett 15, 1621–1629.
- Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D and Tabernero J (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. *Oncologist* 18, 1004–1012.

- Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, et al. (2018) Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab. Oncoimmunology 7, e1457598.
- Jang CW, Shibata Y, Starmer J, Yee D and Magnuson T (2015) Histone H3.3 maintains genome integrity during mammalian development. *Genes Dev* 29, 1377–1392.
- Jiang Q, He M, Guan S, Ma M, Wu H, Yu Z, Jiang L, Wang Y, Zong X, Jin F et al. (2016) MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/betacatenin signaling pathway. *Tumor Biol* 37, 5001–5011.
- Jiao GM, Huang Q, Hu MR, Liang X, Li F, Lan C, Fu W, An Y, Xu B, Zhou J et al. ((2017) Therapeutic suppression of miR-4261 attenuates colorectal cancer by targeting MCC. *Mol Ther Nucleic Acids* 8, 36–45.
- Johannessen C, Moi L, Kiselev Y, Pedersen MI, Dalen SM, Braaten T and Busund LT (2017) Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. *PLoS ONE* 12(10), e0186658.
- Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S and Sahin O (2012) MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actinregulatory proteins FHOD1 and PPM1F. *Mol Cell Biol* 32, 633–651.
- Kent OA and Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. *Oncogene* **25**, 6188–6196.
- Kim JY, Jeong HS, Chung T, Kim M, Lee JH, Jung WH and Koo JS (2017) The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67. *Oncotarget* **8**, 65064–65076.
- Kiss I, Mlcochova J, Souckova K, Fabian P, Poprach A, Halamkova J, Svoboda M, Vyzula R and Slaby O (2017) MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX. *Oncol Lett* **14**, 743–750.
- Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, Kawaguchi M, Kobayashi H, Doi R, Hori T *et al.* (2000) Expression of stromal cell-derived factor 1 and CXCR40 ligand receptor system in pancreatic cancer: A possible role for tumor progression. *Clin Cancer Res* 6, 3530–3535.
- Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V *et al.* (2005) CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. *Can Res* 65, 465–472.

- Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H and Horiguchi J (2017) Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 62, 15–24.
- Lee DY, Deng Z, Wang CH and Yang BB (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. *Proc Natl Acad Sci USA* 104, 20350–20355.
- Leivonen SK, Sahlberg KK, Makela R, Due EU, Kallioniemi O, Borresen-Dale AL and Perala M (2014) High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. *Mol Oncol* 8, 93–104.
- Lewis BP, Burge CB and Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **120**, 15–20.
- Li D, Zhao YL, Liu CX, Chen X, Qi Y, Jiang Y, Zou C, Zhang X, Liu S, Wang X *et al.* (2011) Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. *Clin Cancer Res* **17**, 1722–1730.
- Li NN, Miao Y, Shan YJ, Liu B, Li Y, Zhao LF and Jia L (2017) MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. *Cell Death Dis* **8**, e2796.
- Li P, Sheng C, Huang LL, Zhang H, Huang LH, Cheng ZN and Zhu QB (2014) MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration. *Breast Cancer Res* **16**, 473.
- Li YZ, Wang YX, Fan HZ, Zhang ZY and Li N (2018) miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522. *Biochem Biophys Res Commun* **504**, 277–282.
- Lin YW, Chen H, Hu ZH, Mao Y, Xu X, Zhu Y, Xu X, Wu J, Li S, Mao Q *et al.* (2013) miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. *FEBS Lett* **587**, 2467–2473.
- Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L and Jiang BH (2011) MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. *PLoS ONE* **6**, e19139.
- Loyola A and Almouzni G (2007) Marking histone H3 variants: how, when and why? *Trends Biochem Sci* **32**, 425–433.
- Luo QF, Li XY, Gao Y, Long Y, Chen L, Huang YX and Fang L (2013) MiRNA-497 regulates cell growth and invasion by targeting cyclin E1 in breast cancer. *Cancer Cell Int* **13**, 95.
- Luo TT, Yan YQ, He QX, Ma XQ and Wang W (2018) miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE. *Oncol Rep* **39**, 2906– 2914.
- Macedo T, Silva-Oliveira RJ, Silva VAO, Vidal DO, Evangelista AF and Marques MMC (2017)

Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines. *Oncol Lett* **14**, 1054–1060.

- Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA and Sweep CG (2002) The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. *Br J Cancer* 87, 772–778.
- Mandujano-Tinoco EA, Garcia-Venzor A, Munoz-Galindo L, Lizarraga-Sanchez F, Favela-Orozco A, Chavez-Gutierrez E, Krotzsch E, Salgado RM, Melendez-Zajgla J and Maldonado V (2017) miRNA expression profile in multicellular breast cancer spheroids. *Biochim Biophys Acta Mol Cell Res* 1864, 1642–1655.
- Mao L, Wertzler KJ, Maloney SC, Wang ZP, Magnuson NS and Reeves R (2009) HMGA1 levels influence mitochondrial function and mitochondrial DNA repair efficiency. *Mol Cell Biol* **29**, 5426–5440.
- Maragkakis M, Reczko M, Simossis VA, Alexiou P, Papadopoulos GL, Dalamagas T, Giannopoulos G, Goumas G, Koukis E, Kourtis K *et al.* (2009)
  DIANA-microT web server: elucidating microRNA functions through target prediction. *Nucleic Acids Res* 37, W273–W276.
- McCall MN, Kim MS, Adil M, Patil AH, Lu Y, Mitchell CJ, Leal-Rojas P, Xu J, Kumar M, Dawson VL *et al.* (2017) Toward the human cellular microRNAome. *Genome Res* 27, 1769–1781.
- McKittrick E, Gaften PR, Ahmad K and Henikoff S (2004) Histone H3.3 is enriched in covalent modifications associated with active chromatin. *Proc Natl Acad Sci USA* **101**, 1525–1530.
- Mi HL, Wang XC, Wang F, Li L, Zhu MZ, Wang N, Xiong YY and Gu YT (2018) miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. *Eur J Pharmacol* **839**, 66–75.
- Miles DW, Chan A, Dirix LY,Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F *et al.* (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. *J Clin Oncol* 28, 3239–3247.
- Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. *N Engl J Med* 357, 2666–2676.
- Montero AJ, Escobar M, Lopes G, Gluck S and Vogel C (2012) Bevacizumab in the treatment of metastatic breast cancer: friend or foe? *Curr Oncol Rep* **14**, 1–11.
- Mulrane L, Madden SF, Brennan DJ, Gremel G, McGee SF, McNally S, Martin F, Crown JP, Jirstrom K,

Higgins DG *et al.* (2012) miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential *in vitro. Clin Cancer Res* **18**, 6702–6713.

- Ng EKO, Li R, Shin VY, Siu JM, Ma ESK and Kwong A (2014) MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. *Tumor Biology* **35**, 2591–2598.
- Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC *et al.* (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* 534, 47–54.
- Nilsen G, Borgan O, Liestol K and Lingjaerde OC (2013) Identifying clusters in genomics data by recursive partitioning. *Stat Appl Genet Mol Biol* **12**, 637–652.
- Oliveros JC (2007–2015) Venny. An interactive tool for comparing lists with Venn's diagrams. https://bioinf ogp.cnb.csic.es/tools/venny/index.html
- Pan YZ, Morris ME and Yu AM (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. *Mol Pharmacol* 75, 1374–1379.
- Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T and Hatzigeorgiou AG (2013) DIANAmicroT web server v5.0: service integration into miRNA functional analysis workflows. *Nucleic Acids Res* 41, W169–W173.
- Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol* 27, 1160–1167.
- Pawlyn C, Bright M, Buros A, Stein CK, Walters Z, Aronson L, Mirabella F, Kaiser MF, Jones JR, Walker BA *et al.* (2016) Inhibition of the epigenetic modifier EZH2 upregulates cell cycle control genes to inhibit myeloma cell growth and overcome high-risk disease features. *Blood* 128, 3289.
- Periyasamy-Thandavan S, Burke J, Mendhe B, Kondrikova G, Kolhe R, Hunter M, Isales CM, Hamrick MW, Hill WD and Fulzele S (2018) MicroRNA-141-3p negatively modulates SDF-1 expression in age-dependent pathophysiology of human and murine bone marrow stromal cells. J Gerontol A 74, 1368–1374.
- Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S and Rainaldi G (2006) MicroRNAs modulate the angiogenic properties of HUVECs. *Blood* **108**, 3068–3071.
- R Core Team (2018) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.
- Reeves R (2001) Molecular biology of HMGA proteins: hubs of nuclear function. *Gene* **277**, 63–81.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P *et al.* (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. *Clin Cancer Res* 11, 5678–5685.

Said R, Garcia-Mayea Y, Trabelsi N, Setti Boubaker N, Mir C, Blel A, Ati N, Paciucci R, Hernández-Losa J, Rammeh S *et al.* (2018) Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients. *Mol Biol Rep* 45, 2345–2358.

Schuldenfrei A, Belton A, Kowalski J, Talbot CC, Di Cello F, Poh W, Tsai H-L, Shah SN, Huso TH, Huso DL *et al.* (2011) HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. *BMC Genom* 12, 549–565.

Shah AV, Birdsey GM, Peghaire C, Dufton NP, Yang Y, Weinberg I, Osuna Almagro L, Payne L, Mason JC et al. (2017) The endothelial transcription factor ERG mediates angiopoietin-1-dependent control of Notch signalling and vascular stability. Nat Commun 8, 16002.

Silwal-Pandit L, Nord S, Gythfeldt HV, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T *et al.* (2017) The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer. *Clin Cancer Res* 23, 4662–4670.

Singh R, Yadav V, Kumar S and Saini N (2015) MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep 5, 17454.

Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, Iruela-Arispe ML, Merkenschlager M and Sessa WC (2008) Dicerdependent endothelial microRNAs are necessary for postnatal angiogenesis. *Proc Natl Acad Sci USA* 105, 14082–14087.

Sun J, Tian X, Lu SQ and Hu HB (2017) MicroRNA-4465 suppresses tumor proliferation and metastasis in nonsmall cell lung cancer by directly targeting the oncogene EZH2. *Biomed Pharmacother* 96, 1358–1362.

Sun W, Julie Li YS, Huang HD, Shyy JY and Chien S (2010) microRNA: a master regulator of cellular processes for bioengineering systems. *Annu Rev Biomed Eng* 12, 1–27.

Thanos D and Maniatis T (1995) Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. *Cell* **83**, 1091–1100.

Ueda Y, Watanabe S, Tei S, Saitoh N, Kuratsu JI and Nakao M (2007) High mobility group protein HMGA1 inhibits retinoblastoma protein-mediated cellular G0 arrest. *Cancer Sci* 98, 1893–1901.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R *et al.* (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med* **366**, 299–309.

- Wang J, Guo XJ, Ding YM and Jiang JX (2017) miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. *World J Gastroentero* 23, 1594–1601.
- Wang Q, Su CY, Li JT and Wei CS (2018a) Mechanism of the enhancing effects of miR-93 on resistance of breast cancer MCF-7 cells to adriamycin. *Oncol Lett* 16, 3779–3783.

Wang XY and Zhu JW (2018) Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53. *Thoracic Cancer* **9**, 676–683.

Wang YW, Zhang WG and Ma R (2018b) Bioinformatic identification of chemoresistance-associated microRNAs in breast cancer based on microarray data. *Oncol Rep* 39, 1003–1010.

Wang YL, Zhang XL, Zou C, Kung HF, Lin MC, Dress A, Wardle F, Jiang BH and Lai LH (2016) miR-195 inhibits tumor growth and angiogenesis through modulating IRS1 in breast cancer. *Biomed Pharmacother* 80, 95–101.

Wu ML, Fan BH, Guo QJ, Li Y, Chen R, Lv N, Diao YZ and Luo YS (2018) Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation. *Biol Res* 51, 39.

Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, Jiang X, Tan J, Aau M, Lim CZH *et al.* (2011) Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. *Cell Death Differ* 18, 1771–1779.

Wu ZH, Li XL, Cai XH, Huang CG and Zheng M (2016) miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug. *Tumor Biol* 37, 7939–7950.

Xia M, Li H, Wang JJ, Zeng HJ and Wang SH (2016) MiR-99a suppress proliferation, migration and invasion through regulating insulin-like growth factor 1 receptor in breast cancer. *Eur Rev Med Pharmacol Sci* 20, 1755–1763.

Xu X, Lv YG, Yan CY, Yi J and Ling R (2016) Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. *Biochem Biophys Res Comm* 479, 893–900.

Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL *et al.* (2011) Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. *Breast Cancer Res* 13, R2.

Yan L, Yu M-C, Gao G-L, Liang H-W, Zhou X-Y, Zhu Z-T, Zhang C-Y, Wang Y-B and Chen X (2018) MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. *J Cell Biochem* 119, 8773–8783.

Yang G, Wu DQ, Zhu J, Jiang O, Shi Q, Tian J and Weng YG (2013) Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. *Oncol Rep* **30**, 877–889.

Yoo JO, Kwak SY, An HJ, Bae IH, Park MJ and Han YH (2016) miR-181b-3p promotes epithelialmesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. *Biochim Biophys Acta Mol Cell Res* 1863, 1601–1611.

Yoo KH and Hennighausen L (2012) EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer. *Int J Biol Sci* **8**, 59–65.

Zhang LS, Chen YW, Wang H, Zheng X, Li CH and Han ZX (2018) miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR. Onco Targets Ther 11, 5293–5302.

Zhang Q, Padi SKR and Tindall DJ and Guo B (2014) Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. *Cell Death Dis* **5**, e1486.

Zhang T, Wan JG, Liu JB and Deng M (2017) MiR-200c inhibits metastasis of breast tumor via the downregulation of Foxf2. *Genet Mol Res* **16**, gmr16038971.

Zhang WL and Zhang JH (2015) miR-181c promotes proliferation via suppressing PTEN expression in inflammatory breast cancer. *Int J Oncol* **46**, 2011–2020.

Zhao H, Kang X, Xia XF, Wo LK, Gu XD, Hu YY, Xie XH, Chang H, Lou LH and Shen XN (2016) miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. *Am J Transl Res* 8, 3106–3114.

Zheng YB, Lv XA, Wang XJ, Wang B, Shao XY, Huang Y, Shi L, Chen ZH, Huang J and Huang P (2016) miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. *Oncol Rep* 35, 683–690.

Zhou BT, Wei ED, Shi HL, Huang JF, Gao L, Zhang TY, Wei Y and Ge B (2017) MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity. *Int J Clin Exp Pathol* **10**, 11234–11241.

### **Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1.** Unsupervised hierarchical clustering of miRNA expression from the 48 patients with biopsies from all three time points. Clusters and statistics are based on miRNA expression on week 0, and clusters

are kept for week 12 and week 25. A significant association was identified between the two clusters, OR and tumor stage (T stage).

**Table S1.** miRNAs present within each of the clustersillustrated in Fig. 1.

**Table S2.** Significantly differentially expressed miR-NAs between OR and non-responders at week 0, regardless of treatment arm.

**Table S3.** (A) Significantly differentially expressed miRNAs from week 0 to week 25 in the chemotherapy arm, regardless of treatment response. (B) Significantly differentially expressed miRNAs from week 0 to week 25 in the Bev arm, regardless of treatment response. (C) Significantly differentially expressed miRNAs from week 0 to week 25 in both treatment arms, regardless of treatment response.

**Table S4.** Bivariate regression model wherein protein expression was modeled as a function of powers of mRNA in-*cis* and miRNA expression. The model was applied to mRNA and protein expression for 210 selected cancer-associated genes and the 627 miRNAs studied here. The effect of one miRNA at a time was considered, for all three time points. The beta value indicates the association between a miRNA and a protein.

**Table S5.** (A) Significantly differentially expressed miRNAs between week 0 and week 25 in responding patients in the chemotherapy arm. (B) Significantly differentially expressed miRNAs between week 0 and week 25 in responding patients in the Bev arm. (C) Significantly differentially expressed miRNAs from week 0 to week 25 in both treatment arms, regardless of treatment response.

**Table S6.** Correlations between proliferation score and significantly differentially expressed miRNAs between week 0 and week 25 in Bev-responding patients.

**Table S7.** Correlations between mRNAs and significantly differentially expressed miRNAs between week 0 and week 25 in Bev treated responders.

**Table S8.** Ingenuity pathways derived from genes with significant correlation to the five Bev-associated miR-NAs.

**Table S9.** (A) Significantly differentially expressed mRNAs between week 0 and week 25 within responding patients in the Bev arm. (B) Significantly differentially expressed mRNAs between week 0 and week 25 within responding patients in the chemotherapy arm.